Is CDXS or TKNO more profitable?

Alpha Teknova has a net margin of -34.76% compared to Codexis' net margin of -39.55%. Alpha Teknova's return on equity of -24.95% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Codexis -39.55% -74.36% -23.58% Alpha Teknova -34.76% -24.95% -16.27%

Does the media favor CDXS or TKNO?

In the previous week, Alpha Teknova had 2 more articles in the media than Codexis. MarketBeat recorded 9 mentions for Alpha Teknova and 7 mentions for Codexis. Codexis' average media sentiment score of 0.76 beat Alpha Teknova's score of 0.70 indicating that Codexis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alpha Teknova 1 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SLP or CDXS more profitable?

Simulations Plus has a net margin of 9.88% compared to Codexis' net margin of -39.55%. Simulations Plus' return on equity of 13.50% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Simulations Plus 9.88% 13.50% 12.45% Codexis -39.55% -74.36% -23.58%

Does the media refer more to CDXS or NAUT?

In the previous week, Codexis had 5 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 7 mentions for Codexis and 2 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 0.91 beat Codexis' score of 0.76 indicating that Nautilus Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nautilus Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, CDXS or QSI?

Codexis has higher revenue and earnings than Quantum-Si. Quantum-Si is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Codexis $70.39M 1.56 -$43.97M -$0.34 N/A Quantum-Si $2.44M 114.82 -$101.34M -$0.39 N/A

Is CDXS or QSI more profitable?

Codexis has a net margin of -39.55% compared to Quantum-Si's net margin of -6,729.80%. Quantum-Si's return on equity of -44.72% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Codexis -39.55% -74.36% -23.58% Quantum-Si -6,729.80% -44.72% -41.26%

Does the media favor CDXS or QSI?

In the previous week, Quantum-Si had 4 more articles in the media than Codexis. MarketBeat recorded 11 mentions for Quantum-Si and 7 mentions for Codexis. Codexis' average media sentiment score of 0.76 beat Quantum-Si's score of 0.14 indicating that Codexis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Quantum-Si 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend LAB or CDXS?

Codexis has a consensus price target of $6.50, indicating a potential upside of 550.00%. Given Codexis' stronger consensus rating and higher probable upside, analysts clearly believe Codexis is more favorable than Standard BioTools. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Standard BioTools 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Codexis 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is LAB or CDXS more profitable?

Standard BioTools has a net margin of 157.62% compared to Codexis' net margin of -39.55%. Standard BioTools' return on equity of -5.61% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Standard BioTools 157.62% -5.61% -4.73% Codexis -39.55% -74.36% -23.58%

Does the media prefer LAB or CDXS?

In the previous week, Codexis had 1 more articles in the media than Standard BioTools. MarketBeat recorded 7 mentions for Codexis and 6 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.29 beat Codexis' score of 0.76 indicating that Standard BioTools is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Standard BioTools 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Codexis 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Codexis (CDXS) Competitors

$0.98 -0.02 (-2.36%)

As of 04:00 PM Eastern

Compare

CDXS vs. TKNO, SLP, NAUT, QSI, and LAB

Should you buy Codexis stock or one of its competitors? Codexis's main competitors and comparable companies include Alpha Teknova (TKNO), Simulations Plus (SLP), Nautilus Biotechnology (NAUT), Quantum-Si (QSI), and Standard BioTools (LAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Codexis compare to Alpha Teknova?

Codexis (NASDAQ:CDXS) and Alpha Teknova (NASDAQ:TKNO) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Alpha Teknova has lower revenue, but higher earnings than Codexis. Alpha Teknova is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	1.56	-$43.97M	-$0.34	N/A
Alpha Teknova	$40.52M	13.55	-$17.26M	-$0.29	N/A

Codexis has a beta of 2.38, meaning that its share price is 138% more volatile than the broader market. Comparatively, Alpha Teknova has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

78.5% of Codexis shares are held by institutional investors. Comparatively, 13.8% of Alpha Teknova shares are held by institutional investors. 3.5% of Codexis shares are held by insiders. Comparatively, 13.2% of Alpha Teknova shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Codexis presently has a consensus target price of $6.50, indicating a potential upside of 550.00%. Alpha Teknova has a consensus target price of $8.75, indicating a potential upside of 0.23%. Given Codexis' higher probable upside, equities analysts clearly believe Codexis is more favorable than Alpha Teknova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Alpha Teknova	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Alpha Teknova had 2 more articles in the media than Codexis. MarketBeat recorded 9 mentions for Alpha Teknova and 7 mentions for Codexis. Codexis' average media sentiment score of 0.76 beat Alpha Teknova's score of 0.70 indicating that Codexis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alpha Teknova	1 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alpha Teknova has a net margin of -34.76% compared to Codexis' net margin of -39.55%. Alpha Teknova's return on equity of -24.95% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
Alpha Teknova	-34.76%	-24.95%	-16.27%

Summary

Alpha Teknova beats Codexis on 10 of the 16 factors compared between the two stocks.

How does Codexis compare to Simulations Plus?

Simulations Plus (NASDAQ:SLP) and Codexis (NASDAQ:CDXS) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Codexis has lower revenue, but higher earnings than Simulations Plus. Codexis is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$82.06M	4.56	-$64.72M	$0.40	46.25
Codexis	$70.39M	1.56	-$43.97M	-$0.34	N/A

Simulations Plus presently has a consensus target price of $17.25, indicating a potential downside of 6.76%. Codexis has a consensus target price of $6.50, indicating a potential upside of 550.00%. Given Codexis' stronger consensus rating and higher probable upside, analysts clearly believe Codexis is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.83
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Simulations Plus has a beta of 1.31, indicating that its stock price is 31% more volatile than the broader market. Comparatively, Codexis has a beta of 2.38, indicating that its stock price is 138% more volatile than the broader market.

78.1% of Simulations Plus shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 19.1% of Simulations Plus shares are owned by insiders. Comparatively, 3.5% of Codexis shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Codexis had 7 more articles in the media than Simulations Plus. MarketBeat recorded 7 mentions for Codexis and 0 mentions for Simulations Plus. Codexis' average media sentiment score of 0.76 beat Simulations Plus' score of 0.00 indicating that Codexis is being referred to more favorably in the news media.

Company	Overall Sentiment
Simulations Plus	Neutral
Codexis	Positive

Simulations Plus has a net margin of 9.88% compared to Codexis' net margin of -39.55%. Simulations Plus' return on equity of 13.50% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
Codexis	-39.55%	-74.36%	-23.58%

Summary

Simulations Plus and Codexis tied by winning 8 of the 16 factors compared between the two stocks.

How does Codexis compare to Nautilus Biotechnology?

Codexis (NASDAQ:CDXS) and Nautilus Biotechnology (NASDAQ:NAUT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

Nautilus Biotechnology has a net margin of 0.00% compared to Codexis' net margin of -39.55%. Nautilus Biotechnology's return on equity of -42.68% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
Nautilus Biotechnology	N/A	-42.68%	-34.39%

Codexis has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market. Comparatively, Nautilus Biotechnology has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

78.5% of Codexis shares are owned by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are owned by institutional investors. 3.5% of Codexis shares are owned by company insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Codexis currently has a consensus target price of $6.50, indicating a potential upside of 550.00%. Nautilus Biotechnology has a consensus target price of $3.83, indicating a potential upside of 65.23%. Given Codexis' higher probable upside, research analysts clearly believe Codexis is more favorable than Nautilus Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Nautilus Biotechnology	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Codexis has higher revenue and earnings than Nautilus Biotechnology. Nautilus Biotechnology is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	1.56	-$43.97M	-$0.34	N/A
Nautilus Biotechnology	N/A	N/A	-$59M	-$0.46	N/A

In the previous week, Codexis had 5 more articles in the media than Nautilus Biotechnology. MarketBeat recorded 7 mentions for Codexis and 2 mentions for Nautilus Biotechnology. Nautilus Biotechnology's average media sentiment score of 0.91 beat Codexis' score of 0.76 indicating that Nautilus Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nautilus Biotechnology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Codexis beats Nautilus Biotechnology on 9 of the 15 factors compared between the two stocks.

How does Codexis compare to Quantum-Si?

Codexis (NASDAQ:CDXS) and Quantum-Si (NASDAQ:QSI) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, profitability, risk, media sentiment, analyst recommendations, dividends, earnings and institutional ownership.

Codexis has higher revenue and earnings than Quantum-Si. Quantum-Si is trading at a lower price-to-earnings ratio than Codexis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	1.56	-$43.97M	-$0.34	N/A
Quantum-Si	$2.44M	114.82	-$101.34M	-$0.39	N/A

Codexis has a beta of 2.38, suggesting that its stock price is 138% more volatile than the broader market. Comparatively, Quantum-Si has a beta of 3.26, suggesting that its stock price is 226% more volatile than the broader market.

Codexis presently has a consensus price target of $6.50, indicating a potential upside of 550.00%. Quantum-Si has a consensus price target of $2.50, indicating a potential upside of 95.31%. Given Codexis' higher possible upside, research analysts clearly believe Codexis is more favorable than Quantum-Si.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Quantum-Si	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Quantum-Si had 4 more articles in the media than Codexis. MarketBeat recorded 11 mentions for Quantum-Si and 7 mentions for Codexis. Codexis' average media sentiment score of 0.76 beat Quantum-Si's score of 0.14 indicating that Codexis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Quantum-Si	0 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Codexis has a net margin of -39.55% compared to Quantum-Si's net margin of -6,729.80%. Quantum-Si's return on equity of -44.72% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-39.55%	-74.36%	-23.58%
Quantum-Si	-6,729.80%	-44.72%	-41.26%

78.5% of Codexis shares are held by institutional investors. Comparatively, 39.9% of Quantum-Si shares are held by institutional investors. 3.5% of Codexis shares are held by insiders. Comparatively, 22.0% of Quantum-Si shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Codexis beats Quantum-Si on 9 of the 14 factors compared between the two stocks.

How does Codexis compare to Standard BioTools?

Standard BioTools (NASDAQ:LAB) and Codexis (NASDAQ:CDXS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Standard BioTools has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Codexis has a beta of 2.38, indicating that its stock price is 138% more volatile than the broader market.

Codexis has lower revenue, but higher earnings than Standard BioTools. Codexis is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Standard BioTools	$85.33M	3.08	-$74.90M	$0.22	3.02
Codexis	$70.39M	1.56	-$43.97M	-$0.34	N/A

53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 78.5% of Codexis shares are owned by institutional investors. 26.8% of Standard BioTools shares are owned by company insiders. Comparatively, 3.5% of Codexis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Codexis had 1 more articles in the media than Standard BioTools. MarketBeat recorded 7 mentions for Codexis and 6 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 1.29 beat Codexis' score of 0.76 indicating that Standard BioTools is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Standard BioTools	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Codexis	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Codexis has a consensus price target of $6.50, indicating a potential upside of 550.00%. Given Codexis' stronger consensus rating and higher probable upside, analysts clearly believe Codexis is more favorable than Standard BioTools.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Standard BioTools	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Codexis	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Standard BioTools has a net margin of 157.62% compared to Codexis' net margin of -39.55%. Standard BioTools' return on equity of -5.61% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Standard BioTools	157.62%	-5.61%	-4.73%
Codexis	-39.55%	-74.36%	-23.58%

Summary

Standard BioTools beats Codexis on 8 of the 15 factors compared between the two stocks.

Get Codexis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CDXS vs. The Competition

Export

Metric	Codexis	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$106.93M	$11.23B	$7.89B	$12.22B
Dividend Yield	N/A	1.44%	2.47%	4.44%
P/E Ratio	-2.87	53.08	35.35	30.86
Price / Sales	1.52	7.39	8.40	5.81
Price / Cash	N/A	27.65	22.22	22.66
Price / Book	1.74	4.58	4.43	3.79
Net Income	-$43.97M	$57.48B	$3.50B	$390.16M
7 Day Performance	-9.59%	-0.37%	-0.97%	-1.10%
1 Month Performance	-30.75%	-1.68%	-4.07%	-6.19%
1 Year Performance	-45.76%	21.83%	2.04%	-5.75%

Codexis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CDXS Codexis	3.4803 of 5 stars	$0.98 -2.4%	$6.50 +565.7%	-42.9%	$106.93M	$70.39M	N/A	146	News Coverage Upcoming Earnings
TKNO Alpha Teknova	2.2918 of 5 stars	$7.88 +6.9%	$8.75 +11.0%	+89.4%	$395.79M	$45.95M	N/A	158	Earnings Report Gap Up
SLP Simulations Plus	0.3489 of 5 stars	$18.50 flat	$17.25 -6.8%	N/A	$374.16M	$82.06M	46.25	160
NAUT Nautilus Biotechnology	2.9811 of 5 stars	$2.15 -6.1%	$3.83 +78.3%	+39.8%	$291.68M	$36K	N/A	130	Gap Up
QSI Quantum-Si	3.1716 of 5 stars	$1.17 -9.3%	$2.50 +113.7%	-19.7%	$282.36M	$1.61M	N/A	145	Earnings Report Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CDXS) was last updated on 11/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Codexis (CDXS) Competitors

CDXS vs. TKNO, SLP, NAUT, QSI, and LAB

How does Codexis compare to Alpha Teknova?

Summary

How does Codexis compare to Simulations Plus?

Summary

How does Codexis compare to Nautilus Biotechnology?

Summary

How does Codexis compare to Quantum-Si?

Summary

How does Codexis compare to Standard BioTools?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDXS vs. The Competition

Codexis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Codexis (CDXS) Competitors

CDXS vs. TKNO, SLP, NAUT, QSI, and LAB

How does Codexis compare to Alpha Teknova?

Which has preferable valuation & earnings, CDXS or TKNO?

Which has more volatility & risk, CDXS or TKNO?

Do institutionals & insiders hold more shares of CDXS or TKNO?

Do analysts rate CDXS or TKNO?

Does the media favor CDXS or TKNO?

Is CDXS or TKNO more profitable?

Summary

How does Codexis compare to Simulations Plus?

Which has stronger valuation and earnings, SLP or CDXS?

Do analysts rate SLP or CDXS?

Which has more risk & volatility, SLP or CDXS?

Do institutionals & insiders believe in SLP or CDXS?

Does the media refer more to SLP or CDXS?

Is SLP or CDXS more profitable?

Summary

How does Codexis compare to Nautilus Biotechnology?

Is CDXS or NAUT more profitable?

Which has more volatility & risk, CDXS or NAUT?

Do insiders & institutionals hold more shares of CDXS or NAUT?

Do analysts rate CDXS or NAUT?

Which has higher earnings & valuation, CDXS or NAUT?

Does the media refer more to CDXS or NAUT?

Summary

How does Codexis compare to Quantum-Si?

Which has higher valuation and earnings, CDXS or QSI?

Which has more risk & volatility, CDXS or QSI?

Do analysts prefer CDXS or QSI?

Does the media favor CDXS or QSI?

Is CDXS or QSI more profitable?

Do institutionals and insiders hold more shares of CDXS or QSI?

Summary

How does Codexis compare to Standard BioTools?

Which has more volatility & risk, LAB or CDXS?

Which has better earnings & valuation, LAB or CDXS?

Do insiders & institutionals believe in LAB or CDXS?

Does the media prefer LAB or CDXS?

Do analysts recommend LAB or CDXS?

Is LAB or CDXS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CDXS vs. The Competition

Codexis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools